Tirzepatide
Also known as: Mounjaro, Zepbound, dual GIP/GLP-1
Research on tirzepatide, a dual GIP/GLP-1 receptor agonist, including SURPASS, SURMOUNT, and cardiovascular-focused substudies.
What does the research say about Tirzepatide?
Tirzepatide combines GIP and GLP-1 activity. Published work covers glycemic control, weight reduction, sleep apnea substudies, and emerging cardiovascular outcome readouts.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: Tirzepatide
11 indexed papers matched to curated MeSH concepts in the last 90 days.
2657-P: Who Shapes the GLP-1 Narrative on TikTok: A Cross-Sectional Content Analysis
Cross-sectional analysis identifies engaging GLP-1 content themes from TikTok creators, suggesting implications for patient education.
Tirzepatide in Egypt: A New Era in Type 2 Diabetes and Obesity Management
This review analyzes tirzepatide's effectiveness in managing type 2 diabetes and obesity, suggesting significant implications for treatment in Egypt.
Tirzepatide-associated interstitial kidney injury
Case report reveals worsening renal function in a patient using tirzepatide, suggesting potential nephrotoxicity.
Predictors and Characteristics of Hair Loss Among Users of GLP ‐1 Receptor Agonists: A Cross‐Sectional Analysis
Cross-sectional analysis reveals predictors of hair loss in GLP-1 receptor agonist users, suggesting key clinical implications.
A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder
Case report highlights the psychiatric side effects of GLP-1 receptor agonists in a patient with depression, suggesting caution in their use.
Drug-induced liver injury secondary to tirzepatide
Case report shows hepatotoxicity from tirzepatide in a young woman, indicating potential risks of this drug.
Prevalence of Obesity Medications in the Military Health System: An Update from 2022
Cross-sectional analysis reveals low utilization of obesity medications among military beneficiaries, suggesting potential barriers to access.
Tirzepatide data: safety always comes first!
Review evaluates tirzepatide’s efficacy and safety in type 2 diabetes and obesity, highlighting implications for prescription practices.
Attitudes Toward Injectable GLP‐1 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals
Qualitative interviews reveal healthcare professionals' views on prescribing GLP-1 drugs for obesity treatment, indicating gaps and concerns.
ITU Tier 1+ #32: Pharmaceuticals (Kₚharma)
Randomized trial evaluates pharmaceutical efficacy in pipelines, indicating promising AI integrations.
Researchers studying Tirzepatide
Researcher network data is loading or unavailable for this topic.
Follow Tirzepatide literature with AI-enriched clinical evidence on Synapse.
Search Tirzepatide on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers